MECCs skid in bid to level playing field

Medical education companies meeting privately with regulators aired their disproval of a new policy they say treats them unfairly, but real parity appeared beyond reach.

During a December summit, the Accreditation Council for CME (ACCME) acknowledged that commercial conflicts occur beyond MECCs. Still, according to minutes from the meeting supplied by the North American Association of Medical Education and Communication Companies, ACCME asserted that its current mandate only includes consideration of content and conflict issues related to FDA-regulated companies. “ACCME noted that any change to that might be considered ‘mission creep.'”

For its part, ACCME did agree to put the “level playing field” issue on its agenda for a board meeting scheduled for March, but that's no guarantee the concern will be addressed.

Michael Lemon, NAAMECC president, said the group is “encouraged that ACCME is opening a dialogue with various interests that represent accredited providers. There's a lot of work to be done, and our voice needs to be heard.”

At issue is the ACCME's decision to allow schools, hospitals and societies to be exempt from its expanded definition of a commercial interest (MM&M, November 2007), despite receiving comments from groups that the need for exemptions weakens the policy. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.